Current Report Filing (8-k)
17 8월 2022 - 1:50AM
Edgar (US Regulatory)
0001304741
false
0001304741
2022-08-01
2022-08-01
0001304741
dei:FormerAddressMember
2022-08-01
2022-08-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
___________
FORM
8-K
__________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (date of earliest event reported): August
1, 2022
CANNAGISTICS, INC.
(Exact name of registrant as specified in charter)
| Delaware |
000-55711 |
86-3911779 |
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
|
150 Motor Parkway
Suite 401
Hauppauge, NY |
11788 |
| (Address of principal executive offices) |
(Zip Code) |
Registrant’s telephone number, including area
code: 631-787-8455
2110
5th Avenue
Ronkonkoma, NY
631-676-7230
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below)
[ ] Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14-12)
[ ] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement
communications pursuant to Rule 13ed-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: None.
Indicate by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange.
SECTION
5 – CORPORATE GOVERNANCE AND MANAGEMENT
Item
5.01 Changes in Control of Registrant.
On
August 1, 2022, Regen Biowellness, Inc., the holder of 4,400,000 shares of Series F Preferred Voting Stock, entered into an asset purchase
agreement with Emergent Health Corp. (“OTCPink “EMGE”) for the purchase of all assets and certain liabilities of Regen
Biowellness. The 4,400,000 shares of Series F Preferred Stock of the Registrant which represents voting control over the Registrant.
Therefore,
as a result of the asset purchase agreement, there has been a change of control of the Registrant. Emergent Health Corp. is now the holder
of the Series F Preferred Stoc, representing voting control of the Registrant.
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
Effective
as of August 15, 2022, the following individual was removed by a vote of the majority of shares entitled to vote as a Director of the
Registrant.
| Name | | |
Position |
| Dr. Babik Ghalili | | |
Director | |
|
Effective
as of August 15, 2022, the following resigned as an Officer of the Registrant.
| Name | | |
Position |
| Jim Morrison | | |
President/CEO | |
|
Effective
as of August 15, 2022, the following individual(s) were elected by a vote of the majority of shares
entitled to vote to the positions indicated of the Registrant:
| Name | |
Age | |
Position |
| Jim Morrison | |
| 63 | | |
Director |
| James W. Zimbler | |
| 58 | | |
Director and Interim President/CEO |
Mr.
Zimbler has served as the Registrant’s Vice President of Corporate Finance since November 2021, and prior was the President. He
served as a director of the Company from since November 2017 to November 2021. Previously, from November 17, 2017, until July 1, 2020,
he served as President of the Company in which role he was responsible for strategic decision making, capital expenditure planning and
staffing matters. From December 2017 until June 2019, he served as President and a director of the predecessor iteration of a public
company that is now Enzolytics, Inc., a drug development company. In December 2016 he founded Emerging Growth Advisors, Inc., a consulting
firm providing advisory services related to mergers and acquisitions for corporations including the Company, and now Emerging Capital
Strategies, Ltd., where he has served as President since formation. Prior to founding Emerging Growth Advisors, Inc., Mr. Zimbler served
in a managerial role at other consulting firms, each specializing in mergers and acquisitions, roll ups and turn-around work.
SECTION
9 – FINANCIAL STATEMENTS AND EXHIBITS
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Cannagistics,
Inc.
/s/
James W. Zimbler
James
W. Zimbler
Interim
President/Chief Executive Officer
Date:
August 16, 2022
Cannagistics (CE) (USOTC:CNGT)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
Cannagistics (CE) (USOTC:CNGT)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024
